Compare SOHU & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOHU | PRTA |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.6M | 539.9M |
| IPO Year | 2018 | 2013 |
| Metric | SOHU | PRTA |
|---|---|---|
| Price | $14.74 | $10.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $20.00 | $19.00 |
| AVG Volume (30 Days) | 45.6K | ★ 453.1K |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | $1.61 | $1,111.38 |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $1.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.85 | $4.32 |
| 52 Week High | $17.30 | $11.69 |
| Indicator | SOHU | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 34.49 | 67.58 |
| Support Level | $14.22 | $9.69 |
| Resistance Level | $16.13 | $10.90 |
| Average True Range (ATR) | 0.55 | 0.40 |
| MACD | -0.06 | 0.11 |
| Stochastic Oscillator | 9.78 | 99.15 |
Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.